

- transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. *Arch Dermatol.* 2011;147:790–6, <http://dx.doi.org/10.1001/archdermatol.2011.159>.
16. Arron ST, Raymond AK, Yanik EL, Castenson D, McCulloch CE, Clarke CA, et al. Melanoma Outcomes in Transplant Recipients With Pretransplant Melanoma. *Dermatol Surg.* 2016;42:157–66, <http://dx.doi.org/10.1097/DSS.0000000000000602>.
 17. Zwald F, Leitenberger J, Zeitouni N, Soon S, Brewer J, Arron S, et al. Recommendations for Solid Organ Transplantation for Transplant Candidates With a Pretransplant Diagnosis of Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma and Melanoma: A Consensus Opinion From the International Transplant Skin Cancer Collaborative (ITSCC). *Am J Transplant.* 2016;16:407–13, <http://dx.doi.org/10.1111/ajt.13593>.
 18. Le Mire L, Hollowood K, Gray D, Bordea C, Wojnarowska F. Melanomas in renal transplant recipients. *Br J Dermatol.* 2006;154:472–7, <http://dx.doi.org/10.1111/j.1365-2133.2005.07094.x>.
 19. Fattouh K, Ducroux E, Decullier E, Kanitakis J, Morelon E, Boissonnat P, et al. Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study. *Transpl Int.* 2017;30:1172–80, <http://dx.doi.org/10.1111/tri.13011>.
 20. Garrett GL, Blanc PD, Boscardin J, Lloyd AA, Ahmed RL, Anthony T, et al. Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. *JAMA Dermatol.* 2017;153:296–303, <http://dx.doi.org/10.1001/jamadermatol.2016.4920>.
 21. Brown VL, Matin RN, Cerio R, Leedham-Green ME, Proby CM, Harwood CA. Melanomas in renal transplant recipients: the London experience, and invitation to participate in a European study. *Br J Dermatol.* 2007;156:165–7, <http://dx.doi.org/10.1111/j.1365-2133.2006.07567.x>, author reply 167–169.
 22. Vajdic CM, van Leeuwen MT, Webster AC, McCredie MRE, Stewart JH, Chapman JR, et al. Cutaneous melanoma is related to immune suppression in kidney transplant recipients. *Cancer Epidemiol Biomarkers Prev.* 2009;18:2297–303, <http://dx.doi.org/10.1158/1055-9965.EPI-09-0278>.
 23. Tejera-Vaquero A, Descalzo-Gallego MA, Otero-Rivas MM, Posada-García C, Rodríguez-Pazos L, Pastushenko I, et al. Skin Cancer Incidence and Mortality in Spain: A Systematic Review and Meta-Analysis. *Actas Dermosifiliogr.* 2016;107:318–28, <http://dx.doi.org/10.1016/j.ad.2015.12.008>.
 24. Maor D, Vajdic CM, Cumming S, Fahey V, Bala HR, Snaidr V, et al. Melanoma in a cohort of organ transplant recipients: Experience from a dedicated transplant dermatology clinic in Victoria. Australia. *J Am Acad Dermatol.* 2019, <http://dx.doi.org/10.1016/j.jaad.2019.11.009>.
 25. Hollenbeak CS, Todd MM, Billingsley EM, Harper G, Dyer A-M, Lengerich EJ. Increased incidence of melanoma in renal transplantation recipients. *Cancer.* 2005;104:1962–7, <http://dx.doi.org/10.1002/cncr.21404>.
 26. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. *Nature.* 1999;397:530–4, <http://dx.doi.org/10.1038/17401>.
 27. Geissler EK. Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer? *Transplant Res.* 2015;4:1, <http://dx.doi.org/10.1186/s13737-014-0022-4>.
 28. Knoll GA, Kokolo MB, Mallick R, Beck A, Buenaventura CD, Ducharme R, et al. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data. *BMJ.* 2014;349:g6679.
 29. Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial MDC, Polinsky M, et al. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial. *Transplantation.* 2011;92:303–10, <http://dx.doi.org/10.1097/TP.0b013e3182247ae2>.
 30. Rovira J, Renner P, Sabet-Baktach M, Eggenhofer E, Koehl GE, Lantow M, et al. Cyclosporine A Inhibits the T-bet-Dependent Antitumor Response of CD8(+) T Cells. *Am J Transplant.* 2016;16:1139–47, <http://dx.doi.org/10.1111/ajt.13597>.
 31. Brewer JD. Melanoma in immunosuppressed patients. *Expert Review of Dermatology.* 2010;5:247–50, <http://dx.doi.org/10.1586/edm.10.25>.
 32. Krynitz B, Rozell BL, Lyth J, Smedby KE, Lindelöf B. Cutaneous malignant melanoma in the Swedish organ transplantation cohort: A study of clinicopathological characteristics and mortality. *J Am Acad Dermatol.* 2015;73:106–13.e2, <http://dx.doi.org/10.1016/j.jaad.2015.03.045>.
 33. Williams K, Mansh M, Chin-Hong P, Singer J, Arron ST. Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients. *Clin Infect Dis.* 2014;58:997–1002, <http://dx.doi.org/10.1093/cid/cit940>.
 34. Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology.* 2019;30:1884–901, <http://dx.doi.org/10.1093/annonc/mdz411>.
 35. Park CK, Dahlke EJ, Fung K, Kitchen J, Austin PC, Rochon PA, et al. Melanoma incidence, stage, and survival after solid organ transplant: A population-based cohort study in Ontario, Canada. *J Am Acad Dermatol.* 2020, <http://dx.doi.org/10.1016/j.jaad.2019.09.072>.
 36. Brocard A, Knol A-C, Bossard C, Denis MG, Quéreux G, Saint-Jean M, et al. Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients. *Acta Derm Venereol.* 2017;97:483–8, <http://dx.doi.org/10.2340/00015555-2568>.
 37. Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. *Int J Clin Exp Pathol.* 2012;5:739–53.
 38. Cañueto J, Román-Curto C. Novel Additions to the AJCC's New Staging Systems for Skin Cancer. *Actas Dermosifiliogr.* 2017;108:818–26, <http://dx.doi.org/10.1016/j.ad.2017.05.012>.
 39. Otley CC, Berg D, Ulrich C, Stasko T, Murphy GM, Salasche SJ, et al. Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey. *Br J Dermatol.* 2006;154:395–400, <http://dx.doi.org/10.1111/j.1365-2133.2005.07087.x>.
 40. Garrett GL, He SY, Sabouni N, Daud A, Arron ST. Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature. *JAAD Case Rep.* 2015;1:S23–25, <http://dx.doi.org/10.1016/j.jidcr.2015.09.020>.
 41. Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, et al. Systemic Therapy for Melanoma: ASCO Guideline. *J Clin Oncol.* 2020, <http://dx.doi.org/10.1200/JCO.20.00198>. JCO2000198.
 42. Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. *J Immunother Cancer.* 2019;7:106, <http://dx.doi.org/10.1186/s40425-019-0585-1>.
 43. Afshar K, David S, Fuehner T, Gottlieb J, Gutzmer R. BRAF Inhibition in a Lung Transplant Recipient With Metastatic Melanoma. *JAMA Dermatol.* 2016;152:228–30, <http://dx.doi.org/10.1001/jamadermatol.2015.2910>.
 44. Kanitakis J, Baldassini S, Lora V, Euvrard S. BRAF mutations in melanocytic tumors (nevi and melanomas) from

- organ transplant recipients. *Eur J Dermatol.* 2010;20:167–71, <http://dx.doi.org/10.1684/ejd.2010.0843>.
45. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012;2:401–4, <http://dx.doi.org/10.1158/2159-8290.CD-12-0095>.
 46. Maggiore U, Pascual J. The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients. *Adv Chronic Kidney Dis.* 2016;23:312–6, <http://dx.doi.org/10.1053/j.ackd.2016.08.002>.
 47. Alhamad T, Venkatachalam K, Linette GP, Brennan DC. Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection. *Am J Transplant.* 2016;16:1332–3, <http://dx.doi.org/10.1111/ajt.13711>.
 48. Jose A, Yiannoullou P, Bhutani S, Denley H, Morton M, Picton M, et al. Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature. *Transplant Proc.* 2016;48:3137–41, <http://dx.doi.org/10.1016/j.transproceed.2016.07.019>.
 49. Lipson EJ, Bodell MA, Kraus ES, Sharfman WH. Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma. *J Clin Oncol.* 2014;32:e69–71, <http://dx.doi.org/10.1200/JCO.2013.49.2314>.
 50. Morales RE, Shoushtari AN, Walsh MM, Grewal P, Lipson EJ, Carvajal RD. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. *J Immunother Cancer.* 2015;3:22, <http://dx.doi.org/10.1186/s40425-015-0066-0>.
 51. Qin R, Salama AK. Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus. *Melanoma Manag.* 2015;;2:311–4, <http://dx.doi.org/10.2217/mmt.15.27>.
 52. Ranganath HA, Panella TJ. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma. *J Immunother.* 2015;38:211, <http://dx.doi.org/10.1097/CJI.0000000000000077>.
 53. Spain L, Higgins R, Gopalakrishnan K, Turajlic S, Gore M, Larkin J. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. *Ann Oncol.* 2016;27:1135–7, <http://dx.doi.org/10.1093/annonc/mdw130>.
 54. Barnett R, Barta VS, Jhaveri KD. Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab. *N Engl J Med.* 2017;376:191–2, <http://dx.doi.org/10.1056/NEJMc1614298>.
 55. Boils CL, Aljadir DN, Cantafio AW. Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy. *Am J Transplant.* 2016;16:2496–8, <http://dx.doi.org/10.1111/ajt.13786>.
 56. Lipson EJ, Bagnasco SM, Moore J, Jang S, Patel MJ, Zachary AA, et al. Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. *N Engl J Med.* 2016;374:896–8, <http://dx.doi.org/10.1056/NEJMc1509268>.
 57. Ong M, Ibrahim AM, Bourassa-Blanchette S, Canil C, Fairhead T, Knoll G. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection. *J Immunother Cancer.* 2016;4, <http://dx.doi.org/10.1186/s40425-016-0171-8>.
 58. Herz S, Höfer T, Papanagiotou M, Leyh JC, Meyenburg S, Schadendorf D, et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. *Eur J Cancer.* 2016;67:66–72, <http://dx.doi.org/10.1016/j.ejca.2016.07.026>.
 59. Kuo JC, Lilly LB, Hogg D. Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review. *Melanoma Res.* 2017, <http://dx.doi.org/10.1097/CMR.0000000000000410>.
 60. Kwatra V, Karanth NV, Priyadarshana K, Charakidis M. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report. *J Med Case Rep.* 2017;11:73, <http://dx.doi.org/10.1186/s13256-017-1229-z>.
 61. Hurkmans DP, Verhoeven JGHP, de Leur K, Boer K, Joosse A, Baan CC, et al. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment. *J Immunother Cancer.* 2019;7:182, <http://dx.doi.org/10.1186/s40425-019-0653-6>.
 62. Sunshine JC, Sosman J, Shetty A, Choi JN. Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod Immunotherapy. *J Immunother.* 2020;43:149–52, <http://dx.doi.org/10.1097/CJI.0000000000000319>.